Introduction
============

The bursa of fabricius (BF), or "cloacal thymus", is the primary lymphoid organ in birds. It plays a central role in the proliferation and differentiation of the antibody-producing B lymphocyte lineage[@R1]. Previous studies have shown that some defined peptides sequenced from a BF extract (e.g., bursin and bursal anti-steroidogenic peptide) stimulate specific immune cell subsets[@R2],[@R3] isolated a new pentapeptide, bursopentin (BP5; Cys-Lys-Arg-Val-Tyr), from a BF extract. BP5 was shown to have immunomodulatory effects, including effects on T and B cells, the antioxidant stress response of macrophages, and an inhibitory effect on tumor cell proliferation.

Many studies have focused on BF extracts and multiple biologically active factors and their effects on the humoral immune system in chickens and other birds[@R2]. However, the mechanisms through which these immunomodulatory peptides affect B lineage cell proliferation and antibody production in chickens is poorly understood. DT40 cells are an avian leukosis virus-induced chicken pre-B cell line that express the immunoglobulin M (IgM) isotype B cell reporter in the plasma membrane. DT40 cells are best characterized as a bursal stem cell line[@R4]. Given the unique characteristics of DT40 cells, they have been widely used to observe the biology of pre-B lymphocytes within living cells.

In the present study, the effects of BP5 on the proliferation and cell cycle of DT40 cells were investigated. Furthermore, the role of BP5 in the expression of surface IgM (sIgM) mRNA was determined by real-time polymerase chain reaction (PCR). A gene microarray analysis of DT40 cells treated with or without BP5 was performed to further understand the potential effect of BP5 on pre-B cell development. Signaling pathway and Gene Ontology (GO) analyses were also performed to identify potential signaling pathways involved in these BP5-mediated effects.

Materials and methods
=====================

Cell lines and culture
----------------------

BP5 was synthesized by the Key Laboratory of Animal Immunology of the Ministry of Agriculture (Henan, China). The purity of the synthetic peptide was \> 99%; this was confirmed by reverse-phase high-performance liquid chromatography. DT40 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Gibco) and 5% chicken serum (CHS; Gibco) supplemented with 50 µM β-mercaptoethanol, penicillin (100 IU/ml), and streptomycin (100 µg/ml). The cells were incubated in a humidified incubator containing 5% CO~2~ at 37°C.

Effects of BP5 on DT40 cell proliferation
-----------------------------------------

DT40 cells were allowed to grow until reaching 0.4--0.6 × 10^6^ cells/ml. Then, the cells were collected and washed three times with RPMI 1640 basic medium. The cells were then incubated in tissue culture flasks at different densities (1, 2, and 3 × 10^6^ cells/ml) with varying concentrations (0.02, 0.2, 2, and 20 µg/ml) of BP5 in RPMI 1640 medium (final volume, 10 ml) containing 1% FBS plus 1% CHS or 10% FBS plus 5% CHS, respectively, for 96 h. The cells were harvested at 0, 24, 48, and 72 h post-seeding and quantified using a hemocytometer under a light microscope (Olympus, Tokyo, Japan). Cell viability was assessed by the trypan blue exclusion assay. All experiments were performed in triplicate.

Effects of BP5 on the cell cycle distribution of DT40 cells
-----------------------------------------------------------

DT40 cells (2 × 10^6^ cells/ml) were incubated in tissue culture flasks with varying concentrations (0.02, 0.2, 2, and 20 µg/ml) of BP5 in RPMI 1640 medium (final volume, 10 ml) containing 1% FBS plus 1% CHS for 72 h. The cells were collected 24, 48, and 72 h post-seeding, washed twice with cold phosphate-buffered saline (PBS), resuspended in 70% cold ethanol, and incubated at 4°C for 2 h. Then, the cells were washed with cold PBS and incubated in 0.5 ml of propidium iodide (PI)-binding buffer (50 µg/ml of PI and 100 µg of ribonuclease) at 37°C for 30 min. The cell cycle distribution of DT40 cells was determined on a FACSCaliber flow cytometer with CellQuest Pro analysis software (Becton-Dickinson, Brea, CA, USA). The experiments were performed in triplicate.

Effects of BP5 on sIgM mRNA expression as shown by real-time PCR
----------------------------------------------------------------

Cells were treated with varying concentrations of BP5 (0.02, 0.2, 2, and 20 µg/ml) and collected 24, 48, and 72 h post-seeding. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturers\' instructions. To obtain complementary DNA (cDNA), 2 µg of total RNA was reverse transcribed using a reverse transcription kit (Takara Bio, Shiga, Japan) according to the manufacturer\'s protocol. Each PCR mixture contained 1 µl of template cDNA, 10 µl of 2× SYBR® Green PCR Master Mix, and 5 pmol each of the forward and reverse primers (final volume, 25 µl). The sIgM and control β-actin transcripts were amplified using real-time PCR as per a standard protocol (15 s at 95°C and 30 s at 60°C for 40 cycles, respectively). All reactions were run in triplicate. Relative expression of the sIgM gene was determined according to the 2-ΔΔCT formula. Mean efficiency values were calculated from the amplification profiles of individual samples using LinRegPCR software.

Gene microarray and data analyses
---------------------------------

DT40 cells were incubated for 4 h in the presence or absence of BP5. Total RNA was obtained as described above. The samples were labelled and hybridized according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technologies, Palo Alto, CA, USA). The microarray data were deposited in a Gene Expression Omnibus database under Accession Number GSE30396. The resulting text files were extracted using Agilent Feature Extraction software (ver. 10.5.1.1) and imported into Agilent GeneSpring GX software (ver. 11.0) for further analysis. To determine the genes that were most robustly regulated by BP5, a foldchange threshold of ≥ 2 was applied and compared with control cells treated with PBS.

Statistical analysis
--------------------

All data are presented as the mean ± standard deviation. A P-value \< 0.05 was considered significant. Student\'s t-test was used for the analysis.

Results
=======

BP5 has dual effects on DT40 cell proliferation
-----------------------------------------------

The effect of BP5 on DT40 cell proliferation in two different media varied. In the growth medium (10% FBS plus 5% CHS), the DT40 cells exhibited a rapid increase in number, and BP5 showed no significant effect on the growth curves of DT40 cells (data not shown). However, in the maintenance medium (1% FBS plus 1% CHS), BP5 treatment resulted in dual effects: proliferation (0.02 and 0.2 µg/ml) and the inhibition of proliferation (2 and 20 µg/ml) of DT40 cells 24 and 48 h post-seeding ([Fig. 1](#F1){ref-type="fig"}). The cell counts in the 0.02 and 0.2 µg/ml BP5-treated cells were lower than that in the control group, whereas the cell number following treatment with 20 µg/ml of BP5 was higher than that in the control group 72 h post-seeding. These data indicate that BP5 displays concentration-dependent dual effects on the proliferation of DT40 cells.
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Effects of BP5 on the DT40 cell cycle distribution
--------------------------------------------------

As shown in [Fig. 2](#F2){ref-type="fig"}, the percentage of cells in S phase decreased in all groups when the incubation period was extended. Moreover, the percentages of cells in S phase in the 0.02 and 0.2 µg/ml BP5 treatment groups were significantly higher than that in the control group at 24 and 48 h, respectively. The percentages of cells in G2/M phase in the 2 and 20 µg/ml BP5 treatment groups were higher than that in the control group. These results indicate that 0.02 or 0.2 µg/ml of BP5 treatment promoted cell cycle accumulation in the S phase, whereas 2 or 20 µg/ml of BP5 treatment arrested the cell cycle in G2/M phase, consistent with the results of the cell number and viability assays.
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Effects of BP5 on sIgM mRNA expression in DT40 cells
----------------------------------------------------

The relative sIgM mRNA levels increased in all BP5 treatment groups ([Fig. 3](#F3){ref-type="fig"}). In particular, the sIgM mRNA level at the 20 µg/ml concentration was significantly higher than that in the control group. The increase in sIgM gene expression was enhanced concentration-dependently at 24 h, whereas it declined at 48 h, with no further difference in sIgM expression among these groups at 72 h.
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Analysis of gene expression profiling in BP5-treated DT40 cells

A gene expression profile of DT40 cells after 4 h of incubation with 0.02 µg/ml of BP5 was carried out to further identify the molecular mechanism underlying the effects of BP5 on pre-B lymphocyte biology. As shown in the scatterplot ([Fig. 4A](#F4){ref-type="fig"}), genes above the top green line and below the bottom green line showed a 2.0-fold change, and variations in expression were detected between the treated and control cells. Gene expression profiling revealed that 1,254 genes were upregulated and 1,762 genes were downregulated after BP5 treatment. We also used real-time reverse transcription-PCR (qRT-PCR) to validate the microarray results. The primer sequences of the twelve selected genes are shown in [Table S1](#T1){ref-type="table"}.
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###### 

The primer sequences of the selected genes

  --------------------------------------
  Genes     Primer sequences(5′ to 3′)
  --------- ----------------------------
  GAPDH     TTGACCTGACCTGCCGTCTG\
            TGGCTGTCACCATTGAAGTCAC

  FZR1      TCCTGGGAGCAGGGATTGAG\
            GACTGGAACGTTTGGTGCTGAG

  HDAC1     AGGACTGCCCTGTGTTCGATG\
            TCCTGCCCAATTCACAGCAA

  GDF3      AGAGACCCGGTGGATGGTTGTA\
            ATGGTCAGGCGCTCATCCTC

  FGF3      TGTCGGGATCGTCGCTATCA\
            GGTACAGACGGGATGCATAGGTG

  IRF7      TGAAGGTCAACACACCACAGGAG\
            CCCAACCACAAAGCTTATTGCAG

  DNMT1     AGTCGTGGTTCCAGAGGCAGA\
            CACCAAAGCGCTCATGTCCTTA

  CSNK2A1   CTCCTGTCAGCAGTGCGAGTATG\
            ATGACGGGTGAGCCTGCTAGA

  SKP1      TTAAGCTGCAGAGTTCAGATGGAGA\
            CTGGGTCATCATCGCCTTCA

  RAP1B     CAAGCTAGTGGTTCTTGGTTCTGGA\
            GCATACACTGTTGCGCATCTACTTC

  TCEB1     AGAGCATGCATTAACATCAGGAACA\
            GGTGCAATTGGGAATTCAGGA

  FGF8      TCATCGTCGAGACCGACACC\
            CAGTCCTTGCCTTTGCCGTTA

  TRIP12    GTTTATCATGAGCCCATTCCAACAG\
            TTCCAGCCACATATTAGCAGTGACA
  --------------------------------------

Signaling pathway analysis of differentially expressed genes
------------------------------------------------------------

Signaling pathway and GO analyses were performed to identify the biological functions of the subsets of differentially expressed genes after BP5 treatment. Enriched genes associated with signaling pathways were identified according to the Kyoto Encyclopedia of Genes and Genomes database. Eight signaling pathways were affected by BP5 treatment, including the Toll-like receptor (TLR) signaling pathway, mitogen-activated protein kinase (MAPK) signaling pathway, ubiquitin-mediated proteolysis, and Wnt signaling pathway (Table 1 and [Fig. 4B](#F4){ref-type="fig"}, more information is shown in [Figs. S1](#F5){ref-type="fig"}--[4](#F8){ref-type="fig"}). Most of these signaling pathways are involved in pre-B lymphocyte development and humoral immunity.
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TLR signaling pathway
---------------------

Toll-induced B cell proliferation may be an ancient pathway of the innate immune system[@R5]. The TLR signaling pathway was the most significant pathway with the highest enrichment score (3.214) in DT40 cells after BP5 treatment. Some important genes, including those encoding interferon-beta (IFN-β), IRAK4, and mitogen-activated protein kinase 7 (MAP3K7), were upregulated, whereas IRF7, MYD88, and Ras-related C3 botulinum toxin substrate 1 (RAC1) were downregulated, after PB5 treatment. These results suggest that BP5, which has been reported to be an immunomodulatory factor in birds, produces diverse innate immune responses.

MAPK signaling pathway
----------------------

The MAPK pathway mediates multiple cellular responses, including cell survival, proliferation, differentiation, and apoptosis[@R6]. Except for mitogen-activated protein kinase 3 and RAC1, the expression of fibroblast growth factor (FGF)3 and RAP1B were induced by BP5 treatment, whereas the expression of FGF8, mitogen-activated protein kinase 4, mitogen-activated protein kinase 5, and P21 protein activated kinase 2 (PAK2) was downregulated. The enrichment score for this pathway was 2.829, suggesting that BP5 regulates B cell development through the MAPK signaling pathway.

Ubiquitin-mediated proteolysis
------------------------------

Ubiquitin-mediated proteolysis plays an important role in basic cellular processes such as regulating the cell cycle, modulating immune and inflammatory responses, and controlling signal transduction pathways[@R7]. In this study, the expression of several genes, including those encoding FZR1, transcription elongation factor B (SIII), and transcription elongation factor B (SIII), polypeptide 1 (TCEB1), were upregulated, whereas the expression of SKP1, thyroid hormone receptor interactor 12, F-Box protein 2, and HERC4 were downregulated after BP5 treatment.

Wnt signaling pathway
---------------------

The Wnt signaling pathway plays an important role in cell development and oncogenesis[@R8]. The expression of genes such as MAP3K7, CSNK2A1, and CTNNB1 was upregulated, whereas the expression of RAC1, SKP1, and calcium binding protein p22 was downregulated after PB5 treatment.

Discussion
==========

BF is a unique humoral immune organ of birds that plays an important role in B cell differentiation and antibody production. Increasing attention has been focused on identifying new biopeptides from the BF, and there is increasing evidence that these peptides play a vital role in the B cell array of basic cellular processes[@R9]. A previous study demonstrated that bursal-derived BP5 is a multifunctional immune-inducing factor that upregulates antibody production[@R3]. The present results confirmed the effects of BP5 on cell proliferation, the cell cycle, and sIgM mRNA expression in the avian pre-B cell line DT40. Interestingly, BP5 displayed concentration-dependent dual effects on DT40 cells. A low concentration of BP5 induced DT40 proliferation, while a high concentration of BP5 inhibited DT40 proliferation. The results of the cell cycle and apoptosis investigations were comparable with the DT40 cell growth curve. The low concentration of BP5 induced S phase at 24 h, while the high concentration of BP5 arrested the cell cycle in G2/M phase. A high concentration of BP5 could result in increased apoptosis of DT40 cells (data not shown). It has been reported that cross-linking sIgM on B cells results in different signaling consequences: relatively weak cross-linking of sIgM induces DNA synthesis, whereas intense cross-linking of sIgM results in apoptotic cell death[@R3]. In the present study, sIgM mRNA expression was concentration-dependently enhanced after BP5 treatment. However, the association between enhanced sIgM mRNA expression and DT40 cell apoptosis should be confirmed in future studies.

The gene expression profile of DT40 cells after 4 h of incubation with 0.02 µg/ml of BP5 was determined via gene microarray analysis to further identify the molecular mechanism of BP5 in pre-B lymphocyte biological processes. Cellular signaling pathway analyses indicated that eight signaling pathways were affected by BP5 treatment, including pathways associated with the cell cycle, cell proliferation, and cytokine secretion. Considering that BP5 has dominant effects on immune responses, the present study focused on four signaling pathways associated with immunity and cell development.

TLR-mediated signaling is broadly classified into MyD88-dependent and -independent pathways. TLR-mediated intracellular signal transduction involves utilization of the signaling molecule MyD88, followed by the nuclear translocation of NFκB, activation of the protein kinase B/Akt, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and MAPK, and phosphorylation of the IRF transcription factor family[@R10]. IRAKs are important mediators of TLR-induced intracellular signal transduction as they potentiate downstream signaling. Some studies indicate that IRAK4 and IRAK1 are sequentially phosphorylated and dissociated from MyD88 upon stimulation, resulting in the activation of tumor necrosis factor receptor-associated factor 6[@R11]. In the present study, the MyD88 gene was downregulated in DT40 cells treated with BP5. The IRF7 gene, which was recently identified as a key regulator of type I interferon (IFN) activation, was also downregulated. The IRAK4 and IFN-β genes were upregulated via MyD88-independent pathways, which are associated with the JNK-STAT signaling pathway. These findings indicate that BP5 may regulate IFN-β secretion via MyD88-independent pathways rather than through IRF7.

Given the importance of cross-talk between signaling pathways, it was not surprising that multiple genes (e.g., FGF3, FGF8, and RAP1B) associated with the MAPK and Wnt pathways were affected in BP5-treated DT40 cells. FGF3 and FGF8 are key regulators of biological responses during cell development, and MAPK signaling is the most widely known downstream pathway used by FGF3 and FGF8 during cell developmental processes[@R12]. In the present study, FGF3 and RAP1B were upregulated, while FGF8 was downregulated, in BP5-treated DT40 cells. Furthermore, PAK2, a key factor in the JNK and p38 MAP kinase pathways that is highly associated with cell apoptosis, was downregulated. Moreover, CTNNB1 and CSNK2A1 were induced in BP5-treated DT40 cells, whereas RAC1 was downregulated. β-Catenin, a subunit of the cadherin protein complex, is an intracellular signal transducer that regulates coordination of cell-cell adhesion and gene transcription[@R13]. CSNK2A1 is a subunit of casein kinase 2, which is involved in suppressing apoptosis and cell survival. CSNK2A1 induces resting B cells to enter the cell cycle[@R14]. Protein kinase CK2 alpha is overexpressed in colorectal cancer and modulates cell proliferation and invasion by regulating EMT-related genes[@R15]. These results indicate that BP5 may affect DT40 cell development, including cell proliferation, apoptosis, and antibody production by triggering a complex signaling network.

Additionally, the ubiquitin-mediated proteolysis pathway was significantly enriched, and genes involved in this pathway, including FZR1 and TCEB1, were upregulated, whereas SKP1 and F-BOX2 were repressed in BP5-treated DT40 cells. FZR1 is an important regulator of G1 phase and the loss of it would shorten G1 and lengthen S phase[@R16]. SKP1 is a core component of the SKP Cullin F-box protein complex, a type of ubiquitin ligase that initiates the cell division cycle via the timely destruction of many regulatory proteins. In the present study, the percentage of cells in S phase increased following treatment with 0.02 µg/ml of BP5 compared to control cells, in agreement with previous results. These results indicate that BP5 may regulate genes that control the DT40 cell cycle, resulting in B cell development.

Conclusion
==========

In summary, the present results demonstrate that BP5 exerts a strong regulatory effect on DT40 cell biological processes. The results of the gene microarray analysis revealed the gene expression profile and various signaling pathways mediating the effects of bursal-derived peptides in B cell development. In future, the identified key regulatory genes should be studied to verify the signaling pathways associated with BP5-induced effects.
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